In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Story of the Stent: An Interview with Julio Palmaz

Executive Summary

Arguably the most important medical device launched in the last two decades, coronary stents have a fascinating history, filled with stories of unappreciated potential and developmental missteps. In Vivo interviews the stent's inventor, Julio Palmaz, about the vicissitudes of stents.

You may also be interested in...



Two Physicians' Views from the Device Innovator's Workbench

Interviews with physician/entrepreneurs Michael Lesh, who launched Atrionix, and William New, Jr., founder of Nellcor, discussing moviemaking and the Zen of device start-ups.

More from the Device Innovators' Workbench

Interviews with medical device inventors/entrepreneurs Rodney Perkins, MD, and Mir Imran, discussing their successes, such as Collagen and PercuSurge, and the ones that didn't make it.

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV002092

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel